Kolodgie F D, Farb A, Carlson G C, Wilson P S, Virmani R
Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, D.C. 20306-6000.
J Am Coll Cardiol. 1994 Oct;24(4):1098-108. doi: 10.1016/0735-1097(94)90876-1.
The aim of this study was to assess whether hyperoxic reperfusion contributes to the efficacy of Fluosol 20% or poloxamer 188 for infarct size reduction and whether suppression of polymorphonuclear leukocyte function is responsible for cardioprotection.
The perfluorochemical Fluosol and its detergent component poloxamer 188 limit myocardial reperfusion-induced injury; however, the underlying mechanism(s) are uncertain.
A series of in vivo and ex vivo studies were performed in a 30-min temporary coronary occlusion rabbit model. Before reperfusion, rabbits received a 25-ml/kg infusion of 1) Fluosol; 2) poloxamer 188 (equivalent % w/v to Fluosol, 675 mg/kg body weight); or 3) 5% dextrose (control). In protocol A, animals were subjected to either normoxic or hyperoxic reperfusion; in protocols B and C, hyperoxic reperfusion was studied. In protocol B, myocardial blood flow was assessed. In protocol C, polymorphonuclear leukocyte function and myocardial myeloperoxidase were determined.
In rabbits subjected to normoxic reperfusion, infarct size (normalized to risk region weight) was not significantly different among groups. In rabbits subjected to hyperoxic reperfusion, infarcts were significantly reduced with both poloxamer 188 and Fluosol treatment compared with control animals (p = 0.05 and p = 0.0004, respectively). Blood flow at 3 h of reperfusion within the ischemic endocardium was greater in the Fluosol and poloxamer 188 groups than in the control group (p = 0.001 and p = 0.08, respectively). Myeloperoxidase activity was not affected by treatment, nor was there suppression of polymorphonuclear leukocyte function.
Fluosol and poloxamer 188 reduce infarct size in rabbits subjected to hyperoxic reperfusion. Suppression of polymorphonuclear leukocyte function was not demonstrated, suggesting a greater role for increased arterial oxygen delivery in salvaging ischemic myocardium.
本研究旨在评估高氧再灌注是否有助于氟索20%或泊洛沙姆188减小梗死面积,以及多形核白细胞功能的抑制是否对心脏起保护作用。
全氟化合物氟索及其去污剂成分泊洛沙姆188可限制心肌再灌注损伤;然而,其潜在机制尚不确定。
在30分钟暂时性冠状动脉闭塞兔模型中进行了一系列体内和体外研究。再灌注前,兔接受25ml/kg的以下物质输注:1)氟索;2)泊洛沙姆188(与氟索重量/体积百分比相当,675mg/kg体重);或3)5%葡萄糖(对照)。在方案A中,动物接受常氧或高氧再灌注;在方案B和C中,研究高氧再灌注。在方案B中,评估心肌血流量。在方案C中,测定多形核白细胞功能和心肌髓过氧化物酶。
在接受常氧再灌注的兔中,各治疗组之间梗死面积(以危险区域重量标准化)无显著差异。在接受高氧再灌注的兔中,与对照动物相比,泊洛沙姆188和氟索治疗均显著减小了梗死面积(分别为p = 0.05和p = 0.0004)。氟索组和泊洛沙姆188组缺血心内膜再灌注3小时时的血流量高于对照组(分别为p = 0.001和p = 0.08)。髓过氧化物酶活性不受治疗影响,多形核白细胞功能也未受到抑制。
氟索和泊洛沙姆188可减小接受高氧再灌注兔的梗死面积。未证实多形核白细胞功能受到抑制,提示动脉氧输送增加在挽救缺血心肌方面发挥更大作用。